Navigation Links
Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
Date:3/10/2013

EMBARGOED UNTIL 7:45 PM ET, Sunday, March 10, 2013, Cleveland: Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients darbepoetin alfa does not improve patients' health, nor does it reduce their risk of death from heart failure.

Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco on March 10 and published simultaneously online by the New England Journal of Medicine.

Initiated in 2006, the RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial involved 2,278 anemic heart failure patients at 453 sites in 33 countries. Patients were randomly given either darbepoetin alfa or placebo. In the darbepoetin alfa group, 50.7 percent of the patients experienced death from any cause or hospitalization for worsening heart failure. In the placebo group, 49.5 percent of the patients experienced similar clinical outcomes. The trial was funded by Amgen, the maker of darbepoetin alfa (trade name: Aranesp).

"This landmark study provides answers to caregivers who treat patients with heart failure complicated by anemia," said James Young, M.D., cardiologist and Chair of the Cleveland Clinic Endocrinology & Metabolism Institute, and co-investigator of the RED-HF trial. "Our findings do not support the use of darbepoetin alfa to treat anemic heart failure patients."

Anemia, the lack of red blood cells, is a common and serious problem in people who suffer from heart failure. It can lead to worse quality of life, higher rates of hospitalization and death. Treatment options have focused on correcting anemia with the use of intravenous iron or drugs that stimulate red blood cells.

"The benefits of erythropoietin-stimulating agents (ESAs) such as darbepoetin alfa to treat patients with heart failure and anemia have been questioned due t
'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-296-6012
Cleveland Clinic
Source:Eurekalert

Page: 1 2

Related biology news :

1. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
2. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
3. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
4. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
5. New clinical trial explores novel noninvasive colon cancer screening test
6. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
7. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
8. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. AAO-HNS releases updated Clinical Indicators
11. Sequencing works in clinical setting to help -- finally -- get a diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... an experimental vaccine targeting West Nile virus (WNV) opened ... Center in Bethesda, MD. The vaccine, which will be ... for human clinical studies by researchers at the National ... Center (VRC), and Vical Inc., San Diego, based on ...
... the vertebrate embryo - the establishment of a back ... - turns out to be so important that the ... it happens properly. , The discovery, reported this month ... University of California, Berkeley, finally explains an 80-year-old observation ...
... recently discovered a gene essential to one of the ... use PCD to create a protective zone of dead ... pathogen from spreading. But how the plants keep from ... was a mystery. , Now, in the May 20 ...
Cached Biology News:NIAID begins clinical trial of West Nile virus vaccine 2NIAID begins clinical trial of West Nile virus vaccine 3Scientists discover that three overlapping signals in embryo help get the backbone right 2Scientists discover that three overlapping signals in embryo help get the backbone right 3Scientists discover that three overlapping signals in embryo help get the backbone right 4Scientists discover that three overlapping signals in embryo help get the backbone right 5Plant Sacrifices Cells to Fight Invaders 2
(Date:2/26/2015)... Calif. , Feb. 26, 2015  23andMe, the ... Kate Black as Privacy Officer and Corporate ... and state privacy laws as well as health care ... team, she will be responsible for reviewing, updating and ... in the U.S. and abroad. She joined the company ...
(Date:2/26/2015)... JOLLA, Calif. , Feb. 26, 2015   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and Chief Executive Officer ... Cowen and Company 35 th Annual Healthcare Conference ... The conference is being held at the Boston Marriott ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... US - A team of Bioengineers in the United ... its ability to produce ethanol. The research, published in ... metabolic engineering can be combined for strain improvement, a ... focused their research on Zymomonas mobilis, a bacterium noted ...
... NEW YORK, Dec. 10, 2010 Ramius V&O Acquisition ... announced that it has sent a letter to the ... CYPB ) outlining its willingness to acquire all ... for $5.50 per share.  The offer is conditioned upon ...
... new hand-held medical device will help UK athletes reach ... sporting competitions. UK Sport, the UK,s high performance sports ... organisation to use cutting edge technology developed by Argento ... athletes will be able to monitor various proteins which ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: